This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead?
by Zacks Equity Research
Intercept (ICPT) had a tough time in 2017 after news of death were out related to lead drug's Ocaliva's dosing. We do not expect a phenomenal revival in 2018 either.
Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?
by Zacks Equity Research
Celgene's (CELG) stock has been under pressure due to pipeline setbacks. We expect an acquisition in the offing to bolster its portfolio.
5 of the Best-Performing Biotech Stocks of 2017
by Arpita Dutt
With 2017 coming to an end, it is time to take a look at the performance of the biotech sector and some of the best-performing biotech stocks including XOMA (XOMA).
4 Biotech Stocks Ready to Crush the Market in 2018
by Zacks Equity Research
The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2018
by Arpita Dutt
Immuno-oncology was a key focus area in 2017 - will it remain so in 2018 as companies like Juno (JUNO) progress with their pipelines?
CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More
by Zacks Equity Research
The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.
Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs
by Arpita Dutt
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
Juno Reports Additional Data on CAR-T Therapy, Shares Drop
by Zacks Equity Research
Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017.
Bluebird's Shares Jump on Strong Data for CAR-T Therapy
by Zacks Equity Research
bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.
Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta
by Zacks Equity Research
Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma.
Novartis Reports Updated Results from Kymriah's JULIET Study
by Zacks Equity Research
Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.
Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
by Ryan McQueeney
Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.
Company News For Dec 11, 2017
by Zacks Equity Research
Companies in the news are: GILD,AOBC,UNFI,UAL
3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise
by Arpita Dutt
With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.
Gilead Sciences to Acquire Cell Design Labs for $567 Million
by Zacks Equity Research
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?
by Zacks Equity Research
Quite a few pharmaceutical industry mergers may be in the cards in 2018 if the proposed tax reforms are finally approved.
Glaxo Begins Phase III Study on Injection to Prevent HIV
by Zacks Equity Research
Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.
5 Biotech and Pharma Stocks with FDA Catalysts this December
by Arpita Dutt
As we enter the last month of the year, here is a look at some pharma and biotech companies including Amgen (AMGN) that await a decision from the FDA for label expansions or new drugs.
How Will U.S. Tax Reform Impact Pharma/Biotech Industry?
by Zacks Equity Research
After certain modifications to the original plan over the past year, the tax reform bill is expected to be voted on by the Congress this week. Let's see how this vote will impact the pharma/biotech industry.
Glaxo, Pfizer's ViiV Healthcare Begins HIV Drug Combo Study
by Zacks Equity Research
Glaxo (GSK) and partner Pfizer's ViiV Healthcare commences a phase III study on combo regimen of cabotegravir and rilpivirine for treatment of adults with virally suppressed HIV-1 infection.
Gilead (GILD) Down 7.9% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Gilead (GILD) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAR-T Therapy Space 2017 Progress Report
by Zacks Equity Research
Given the vast potential of the CAR T therapy space and two recent approvals, biotech companies are leaving no stone unturned to develop their pipeline candidates.
Biotech Poised for Growth: 3 Healthy Fund Choices
by Zacks Equity Research
The decline in biotech stocks is momentary and we expect the industry to bounce back in the coming days. So consider investing in these three biotech mutual funds.
J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen
by Zacks Equity Research
J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.
United Therapeutics PAH Drug's Exclusivity Period Extended
by Zacks Equity Research
United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.